Granules India’s arm gets USFDA approval for Dofetilide capsules

18 Oct 2021 Evaluate

US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of Granules India for Dofetilide Capsules, 125 meg, 250 meg, and 500 meg. It is bioequivalent to the reference listed drug product (RLD), Tikosyn Capsules, 125 meg, 250 meg, and 500 meg, of Pfizer Inc. This product would be manufactured at the GPI facility located in Chantilly, Virginia, USA and is expected to be launch soon. 

Granules now has a total of 45 ANDA approvals from US FDA (43 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

598.65 -4.65 (-0.77%)
30-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.80
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 902.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×